Cargando…

Feasibility study of portable technology for weight loss and HbA1c control in type 2 diabetes

BACKGROUND: The study investigated the feasibility of conducting a future Randomised Controlled Trial (RCT) of a mobile health (mHealth) intervention for weight loss and HbA1c reduction in Type 2 Diabetes Mellitus (T2DM). METHODS: The intervention was a small wearable mHealth device used over 12 wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Bentley, Claire L., Otesile, Olubukola, Bacigalupo, Ruth, Elliott, Jackie, Noble, Hayley, Hawley, Mark S., Williams, Elizabeth A., Cudd, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946211/
https://www.ncbi.nlm.nih.gov/pubmed/27418275
http://dx.doi.org/10.1186/s12911-016-0331-2
_version_ 1782442987961188352
author Bentley, Claire L.
Otesile, Olubukola
Bacigalupo, Ruth
Elliott, Jackie
Noble, Hayley
Hawley, Mark S.
Williams, Elizabeth A.
Cudd, Peter
author_facet Bentley, Claire L.
Otesile, Olubukola
Bacigalupo, Ruth
Elliott, Jackie
Noble, Hayley
Hawley, Mark S.
Williams, Elizabeth A.
Cudd, Peter
author_sort Bentley, Claire L.
collection PubMed
description BACKGROUND: The study investigated the feasibility of conducting a future Randomised Controlled Trial (RCT) of a mobile health (mHealth) intervention for weight loss and HbA1c reduction in Type 2 Diabetes Mellitus (T2DM). METHODS: The intervention was a small wearable mHealth device used over 12 weeks by overweight people with T2DM with the intent to lose weight and reduce their HbA1c level. A 4 week maintenance period using the device followed. The device records physical activity level and information about food consumption, and provides motivational feedback based on energy balance. Twenty-seven participants were randomised to receive no intervention; intervention alone; or intervention plus weekly motivational support. All participants received advice on diet and exercise at the start of the study. Weight and HbA1c levels were recorded at baseline and weeks 6, 12, and 16. Qualitative interviews were conducted with participants who received the intervention to explore their experiences of using the device and involvement in the study including the training received. RESULTS: Overall the device was perceived to be well-liked, acceptable, motivational and easy to use by participants. Some logistical changes were required during the feasibility study, including shortening of the study duration and relaxation of participant inclusion criteria. Descriptive statistics of weight and HbA1c data showed promising trends of weight loss and HbA1c reduction in both intervention groups, although this should be interpreted with caution. CONCLUSIONS: A number of methodological recommendations for a future RCT emerged from the current feasibility study. The mHealth device was acceptable and promising for helping individuals with T2DM to reduce their HbA1c and lose weight. Devices with similar features should be tested further in larger studies which follow these methodological recommendations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12911-016-0331-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4946211
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49462112016-07-16 Feasibility study of portable technology for weight loss and HbA1c control in type 2 diabetes Bentley, Claire L. Otesile, Olubukola Bacigalupo, Ruth Elliott, Jackie Noble, Hayley Hawley, Mark S. Williams, Elizabeth A. Cudd, Peter BMC Med Inform Decis Mak Research Article BACKGROUND: The study investigated the feasibility of conducting a future Randomised Controlled Trial (RCT) of a mobile health (mHealth) intervention for weight loss and HbA1c reduction in Type 2 Diabetes Mellitus (T2DM). METHODS: The intervention was a small wearable mHealth device used over 12 weeks by overweight people with T2DM with the intent to lose weight and reduce their HbA1c level. A 4 week maintenance period using the device followed. The device records physical activity level and information about food consumption, and provides motivational feedback based on energy balance. Twenty-seven participants were randomised to receive no intervention; intervention alone; or intervention plus weekly motivational support. All participants received advice on diet and exercise at the start of the study. Weight and HbA1c levels were recorded at baseline and weeks 6, 12, and 16. Qualitative interviews were conducted with participants who received the intervention to explore their experiences of using the device and involvement in the study including the training received. RESULTS: Overall the device was perceived to be well-liked, acceptable, motivational and easy to use by participants. Some logistical changes were required during the feasibility study, including shortening of the study duration and relaxation of participant inclusion criteria. Descriptive statistics of weight and HbA1c data showed promising trends of weight loss and HbA1c reduction in both intervention groups, although this should be interpreted with caution. CONCLUSIONS: A number of methodological recommendations for a future RCT emerged from the current feasibility study. The mHealth device was acceptable and promising for helping individuals with T2DM to reduce their HbA1c and lose weight. Devices with similar features should be tested further in larger studies which follow these methodological recommendations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12911-016-0331-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-15 /pmc/articles/PMC4946211/ /pubmed/27418275 http://dx.doi.org/10.1186/s12911-016-0331-2 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bentley, Claire L.
Otesile, Olubukola
Bacigalupo, Ruth
Elliott, Jackie
Noble, Hayley
Hawley, Mark S.
Williams, Elizabeth A.
Cudd, Peter
Feasibility study of portable technology for weight loss and HbA1c control in type 2 diabetes
title Feasibility study of portable technology for weight loss and HbA1c control in type 2 diabetes
title_full Feasibility study of portable technology for weight loss and HbA1c control in type 2 diabetes
title_fullStr Feasibility study of portable technology for weight loss and HbA1c control in type 2 diabetes
title_full_unstemmed Feasibility study of portable technology for weight loss and HbA1c control in type 2 diabetes
title_short Feasibility study of portable technology for weight loss and HbA1c control in type 2 diabetes
title_sort feasibility study of portable technology for weight loss and hba1c control in type 2 diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946211/
https://www.ncbi.nlm.nih.gov/pubmed/27418275
http://dx.doi.org/10.1186/s12911-016-0331-2
work_keys_str_mv AT bentleyclairel feasibilitystudyofportabletechnologyforweightlossandhba1ccontrolintype2diabetes
AT otesileolubukola feasibilitystudyofportabletechnologyforweightlossandhba1ccontrolintype2diabetes
AT bacigaluporuth feasibilitystudyofportabletechnologyforweightlossandhba1ccontrolintype2diabetes
AT elliottjackie feasibilitystudyofportabletechnologyforweightlossandhba1ccontrolintype2diabetes
AT noblehayley feasibilitystudyofportabletechnologyforweightlossandhba1ccontrolintype2diabetes
AT hawleymarks feasibilitystudyofportabletechnologyforweightlossandhba1ccontrolintype2diabetes
AT williamselizabetha feasibilitystudyofportabletechnologyforweightlossandhba1ccontrolintype2diabetes
AT cuddpeter feasibilitystudyofportabletechnologyforweightlossandhba1ccontrolintype2diabetes